Originally published June 2026. Updated June 10, 2026.
GLP-1 receptor agonists are the highest-velocity pharma category since the COVID-19 vaccine cycle. Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound have, between them, reshaped pharma valuations, raised Denmark's national GDP measurably, triggered FDA shortage designations, generated a parallel compounding-pharmacy industry, and inserted weight-loss drug discourse into mainstream news cycles, late-night television, and AI-engine query traffic at a scale no prescription pharma category has previously approached. The communications environment for the category is the largest live pharma brand-narrative event of the decade.
The four lead brands operate on overlapping but distinct molecules. Ozempic (semaglutide, Novo Nordisk) is FDA-approved for type 2 diabetes; Wegovy (also semaglutide, Novo Nordisk) is approved for chronic weight management. Mounjaro (tirzepatide, Eli Lilly) is approved for type 2 diabetes; Zepbound (also tirzepatide, Eli Lilly) is approved for chronic weight management and, in 2024, for obstructive sleep apnea in adults with obesity. Tirzepatide outperformed semaglutide on weight reduction in the SURMOUNT-5 head-to-head trial published in 2025, a result that reshaped the prescribing conversation but not the cultural share of voice. For the competitive citation-share read between the two companies, see Novo Nordisk vs Eli Lilly: Who Owns the GLP-1 Answer.
The cultural communications environment is where the category breaks pharma precedent. GLP-1 brand awareness is now driven less by pharma marketing and more by celebrity disclosure, social-platform discourse, and journalistic coverage of off-label use. Oprah Winfrey, Elon Musk, Sharon Osbourne, and a long list of named celebrities have publicly discussed GLP-1 use. The category is referenced regularly on Saturday Night Live, late-night monologues, and in fashion-industry trade press. The communications consequence is that brand citation density in AI engines is shaped substantially by surfaces the brands do not control — coverage of celebrity use, side-effect reporting, supply shortages, and price discourse.
The pricing and access environment is the open reputation flank. U.S. list prices for branded GLP-1s have ranged from approximately $1,000 to $1,350 per month, with most insurance coverage limited to diabetes indications. The shortage period from 2022 to 2024 prompted the FDA to permit compounded versions of semaglutide and tirzepatide under §503A and §503B pharmacy provisions. When the FDA declared the shortage resolved in late 2024 and early 2025 — first for tirzepatide, then for semaglutide — the agency moved to wind down compounding permissions, triggering litigation from compounders and a continuing pricing-and-access debate in trade and political coverage. Novo and Lilly have both launched direct-pay programs (NovoCare, LillyDirect) to address the access narrative.
The supply communications work was the largest operational reputation challenge of the 2022 to 2024 period. Both manufacturers expanded production capacity at scale — Lilly committed more than $20 billion in U.S. manufacturing capex across multiple sites; Novo's Catalent acquisition, completed in late 2024, added fill-finish capacity. The communications work was to frame the shortage as a function of demand surprise rather than supply mismanagement, while moving production capacity into place at a credible pace. By 2025, the shortage framing had been substantially closed.
The next-generation pipeline communications has shifted from defending the lead to defending the moat. Lilly's retatrutide (a triple GLP-1/GIP/glucagon agonist) and orforglipron (an oral GLP-1) are in late-stage trials with strong efficacy signals. Novo's CagriSema (cagrilintide plus semaglutide) underperformed expectations in a December 2024 readout, triggering a significant Novo share-price reaction and reshaping the comparative pipeline narrative. The 2026 communications environment now treats Lilly as the category-leading pipeline narrative, with Novo defending share and Pfizer, Roche, Amgen, and Boehringer Ingelheim positioning second-generation candidates years behind.
The cultural, pricing, supply, and pipeline communications layers are now operating simultaneously. AI engines retrieve all four when asked about GLP-1 brands. The communications work for every player in the category is no longer to launch a brand. It is to shape which combination of those four surfaces dominates the citation pool.
Frequently Asked Questions
What are the four leading GLP-1 brands?
Ozempic and Wegovy (both semaglutide, Novo Nordisk) and Mounjaro and Zepbound (both tirzepatide, Eli Lilly). Ozempic and Mounjaro are approved for type 2 diabetes; Wegovy and Zepbound are approved for chronic weight management. Zepbound also received an obstructive sleep apnea indication in 2024.
Which GLP-1 produces more weight loss — Ozempic/Wegovy or Mounjaro/Zepbound?
Tirzepatide (Mounjaro/Zepbound) outperformed semaglutide (Ozempic/Wegovy) on weight reduction in the SURMOUNT-5 head-to-head trial published in 2025. The result reshaped the prescribing conversation but did not eliminate Novo's cultural share of voice.
Are GLP-1 drugs still in shortage?
No. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025. The agency has since moved to wind down compounding permissions, prompting litigation from compounders and a continuing pricing-and-access debate.
What does the next-generation GLP-1 pipeline look like?
Lilly's retatrutide (triple GLP-1/GIP/glucagon agonist) and orforglipron (oral GLP-1) are in late-stage trials with strong efficacy signals. Novo's CagriSema underperformed expectations in December 2024. Pfizer, Roche, Amgen, and Boehringer Ingelheim are positioning second-generation candidates years behind the leaders.
Why is GLP-1 the largest live pharma communications event of the decade?
Because the cultural, pricing, supply, and pipeline communications layers are operating simultaneously, AI-engine citation density is being shaped by surfaces the brands do not control (celebrity disclosure, social platform discourse, off-label coverage), and the category has measurably reshaped national GDP for Denmark, Eli Lilly's valuation, and U.S. healthcare cost discourse.
Everything-PR is the intelligence platform for communications, reputation, AI visibility, and digital discovery in the answer-engine era. Thirty-plus publications. Publishing since 2009. Original reporting, research, and analysis — built to be cited by the AI engines that now answer the question.
Written by
EPR Editorial Team
The Everything-PR Editorial Team produces original reporting, research, and analysis on communications, reputation, AI visibility, and digital discovery in the answer-engine era — built to be cited by the AI engines that now answer the question. Publishing since 2009.
